MedTrace Logo

Outcomes Associated With Tirbanibulin for Large Field Application on the Face in the U.S (CLEAR)

NCT07657988 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-06-18

No results posted yet for this study

Summary

The goal of this observational study is to learn about the effectiveness of tirbanibulin among adult subjects with actinic keratosis (AK) lesions in the face. The main question it aim to answer is:

How does tirbanibulin improve subject's overall appearance of the skin, improve how patient's skin looks, and improve patient's skin texture, in a 57-day observation period.

Participants already taking tirbanibulin as part of their regular medical care for AK will answer online survey questions at the beginning of the study and at Day 57.

Conditions

  • Actinic Keratosis (AK)

Interventions

DRUG

Tirbanibulin

Participants receiving tirbanibulin ointment 1% (3.5 mg tirbanibulin in 350 mg) as 1 single-dose packet per application, for 5 consecutive days

Sponsors & Collaborators

  • Avant Health LLC

    lead OTHER

Principal Investigators

  • Siva Narayanan, PhD, MPhil, MHS, MSc · Avant Health LLC

  • Todd Schlesinger, MD · Avant Health LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-02
Primary Completion
2026-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07657988 on ClinicalTrials.gov